No abstract

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction origin that causes persistent fatigue and weakening of voluntary muscles. MG is the most prevalent neuromuscular junction disorder, with an estimated 150-200 new cases per million individuals per year. Patients with MG presently lack a specific and effective long-term therapeutic option. Patients with generalized MG who test positive for anti-acetylcholine receptor antibodies have demonstrated a positive response to Efgartigimod therapy. Thus, the clinical trial of Efgartigimod for the treatment of generalized MG is a significant step toward the availability of an internationally licensed medicine for the ailment.

Irritable Bowel Syndrome (IBS) is a chronic, one of the commonest and persistent gastrointestinal (GI) disorder. Previously, the management plan for IBS-D included enhancing awareness; first line treatment included an increased dietary fiber intake, opioids for diarrhea and antispasmodics for pain management. A recent treatment guideline by the American Gastroenterology Association (AGA) suggests a modified approach to treating patients with IBS-D. Eight drug recommendations were made, and a set of instructions on when to employ which medication was devised. With the incorporation of these structured guidelines, a more tailored and focused approach to IBS management may become plausible.

No abstract

No abstract